---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-012074"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:58:21.571275+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva gains FDA alignment on Phase 3 RECOVER-2 study for brilaroxazine in schizophrenia

## Summary
- FDA accepts 4-week RECOVER-2 study; two positive Phase 3 studies plus 12-month safety could support NDA.
- Topline data from 1-year OLE long-term safety trial expected Q4 2024; NDA submission targeted by Q3 2025.
- RECOVER-2 is a 450-patient global Phase 3 trial; primary endpoint is PANSS total score change at Day 28.
- Company plans to initiate first clinical site in Q2 2024.

## SEC filing metadata
- accession: 0001437749-24-012074
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924012074/0001437749-24-012074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924012074/rvph20240415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-012074
- JSON: https://secwatch.observer/filing/0001437749-24-012074.json
- Plain text: https://secwatch.observer/filing/0001437749-24-012074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.